Align Technology, Inc.

Align Technology, Inc. (ALGN) Market Cap

Align Technology, Inc. has a market capitalization of .

No quote data available.

CEO: Joseph Hogan

Sector: Healthcare

Industry: Medical - Devices

IPO Date: 2001-01-30

Website: https://www.aligntech.com

Align Technology, Inc. (ALGN) - Company Information

Market Cap: -|Sector: Healthcare

Company Profile

Align Technology, Inc. is a medical technology enterprise that develops, produces, and markets its leading products: Invisalign transparent dental aligners and iTero digital intraoral scanners, along with related services. These offerings serve a wide range of dental professionals, including orthodontists, general dentists, and those specializing in restorative and cosmetic dentistry. The company's operations are divided into two main business units: "Clear Aligner" and "Scanners and Services." The Clear Aligner segment offers a variety of solutions. Its comprehensive products include the full Invisalign treatment for teenage patients, designed to address complex orthodontic needs such as mandibular advancement, patient compliance tracking, and managing tooth eruption. It also features specialized Invisalign First Phase I and Phase 2 packages for younger children, typically aged seven to ten, who have mixed dentition (a combination of primary and permanent teeth). Beyond these, the segment provides non-comprehensive aligner options like Invisalign moderate, lite, express, and Invisalign Go. Additional non-case products include retention devices, fees for Invisalign training, and sales of ancillary items such as cleaning materials and adjustment tools used by dental practitioners during treatment. The Scanners and Services segment centers around the iTero scanner, a unified hardware platform offering various software applications for both restorative and orthodontic procedures. It supplies specialized restorative software to general dentists, prosthodontists, periodontists, and oral surgeons, as well as distinct software for orthodontists to manage digital patient records, perform diagnoses, and facilitate the fabrication of printed models and retainers. This segment also provides computer-aided design and manufacturing (CAD/CAM) services, along with supplementary products like disposable covers for the scanner wand and iTero models and dies. Furthermore, it includes third-party scanners and digital scan solutions, the Invisalign Outcome Simulator (a chair-side and cloud-based application for the iTero scanner), the Invisalign Progress Assessment tool, and TimeLapse technology, which enables clinicians to compare a patient's historical 3D scans against current data. Align Technology distributes its products worldwide, with a strong presence in the United States, Switzerland, and China. Founded in 1997, the company is headquartered in Tempe, Arizona.

Analyst Sentiment

74%
Strong Buy

From 17 Active Polls

1Y Forecast: $204.90

▲ +0.0% Potential Upside

Consensus Target Metrics

Low Bound

$188

Median

$200

High Bound

$235

Average

$205

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$204.90
▲ +21.13% Upside
Low Target
$188.00
11% Risk
Median Target
$200.00
18% Mid
High Target
$235.00
39% Max

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

Sentiment volume allocation data unavailable.

Historical valuation matrix unavailable.

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 ALIGN TECHNOLOGY INC (ALGN) — Investment Overview

🧩 Business Model Overview

ALIGN TECHNOLOGY INC operates in an integrated, digital orthodontics workflow. Dental professionals (orthodontists and other prescribing clinicians) acquire patient records, scan or capture 3D information using ALIGN’s imaging ecosystem, and then receive treatment plans and manufacturing fulfillment for clear aligner therapy. The economic flow is tied to per-case treatment delivery, with recurring elements coming from ongoing clinical use of the imaging platform and ancillary components that support continued treatment refinement and retention.

The core “stickiness” is structural: ALIGN’s system is not only a product (aligners), but a tightly coupled software-and-manufacturing process that clinicians and patients experience as one treatment pathway—from capture to plan to production—creating practical friction to switch to alternative platforms once a practice has standardized its workflow.

💰 Revenue Streams & Monetisation Model

Revenue is primarily driven by case-based aligner therapy, including initial aligners and supporting components used throughout a treatment course. A second pillar comes from digital imaging and related offerings that enable clinics to capture accurate 3D records and support treatment planning.

Margin drivers are typically a function of:

  • Manufacturing scale and process yield: aligner production benefits from standardized workflows, centralized production, and continuous process optimization.
  • Product mix: higher-complexity treatments generally command higher economics per patient course versus entry-level cases.
  • Workflow digitization: tighter integration between imaging capture and manufacturing planning reduces rework and improves case throughput.
  • Installed base monetisation (imaging ecosystem): clinics using ALIGN’s imaging infrastructure tend to generate repeat demand for software-enabled capture and service components tied to ongoing clinical operations.

🧠 Competitive Advantages & Market Positioning

ALIGN’s competitive advantages center on a digital orthodontic ecosystem that creates switching costs and an embedded clinical workflow.

  • High Switching Costs (Workflow + Case Data)
    Once a practice standardizes on ALIGN’s scanning, planning, and manufacturing process, changing suppliers can require workflow redesign, staff training, and a re-architecture of how patient records are captured and transmitted. Treatment planning processes and clinician familiarity raise the cost of switching for both providers and—indirectly—patients.
  • Intangible Asset: Clinical Protocol & Software Integration
    ALIGN benefits from accumulated know-how embedded in its treatment planning approach, digital workflow, and manufacturing execution—an asset that is difficult to replicate quickly because it spans both technology and clinical operations.
  • Cost Advantages Through Digitized Scale
    Digitization supports more consistent manufacturing outputs and reduces inefficiency versus less standardized approaches.

Competitive benchmarking (clear aligners and digital orthodontics):

  • Dentsply Sirona (e.g., SureSmile-enabled clear aligner workflows): strong presence in dental technology; competes on digital orthodontic tooling and treatment planning capabilities.
  • Straumann (e.g., ClearCorrect and aligner-adjacent offerings): competes via established brand footprint and orthodontic product breadth.
  • GC Orthodontics (clear aligner systems and related orthodontic solutions): competes on product offerings and clinician channel relationships.

Compared with these rivals, ALIGN is positioned as a more tightly integrated end-to-end ecosystem spanning imaging capture, digital treatment planning, and aligner manufacturing execution—raising practical barriers to switching for practices that have standardized on the full workflow.

🚀 Multi-Year Growth Drivers

Over a 5–10 year horizon, growth is supported by secular penetration of clear aligners and broader adoption of digital orthodontic workflows:

  • TAM expansion via treatment penetration: clear aligners broaden the addressable market by improving cosmetic acceptance versus traditional braces, expanding adoption beyond only the most price-insensitive or most conventionally aligned patient segments.
  • Digital workflow adoption: clinics increasingly choose digital records and treatment planning because it improves precision, reduces operational friction, and supports scalable case management.
  • Practice conversion: the installed base of clinicians using digital capture and planning tools tends to expand use depth as staff training, referral patterns, and operational familiarity accumulate.
  • International growth: orthodontic modernization and rising digital adoption continue to create incremental opportunities for clear aligners and imaging ecosystems in underpenetrated markets.

ALIGN’s structural position is that each incremental case delivered reinforces the clinic’s established workflow, supporting long-run share durability even when competitors offer comparable aligner products.

⚠ Risk Factors to Monitor

  • Competitive technology and pricing pressure: competitors can narrow differentiation through improved software, manufacturing capabilities, and promotional pricing—potentially affecting mix and economics per case.
  • Regulatory and clinical safety oversight: orthodontics involves medical-device and treatment-protocol scrutiny. Changes in regulatory expectations or guidance can impact workflows, documentation, and commercialization economics.
  • Channel concentration and adoption friction: ALIGN depends on practitioner adoption and standardized workflows; shifts in clinician preferences or reimbursement dynamics can slow conversion.
  • Manufacturing capacity and operational execution: scaling production while maintaining quality across varied case complexity creates execution risk.
  • Technological disruption: advances in imaging, new aligner materials, or fundamentally different treatment modalities could reduce the relative advantage of existing workflow integrations.

📊 Valuation & Market View

Valuation for digital orthodontics businesses typically reflects a combination of:

  • Growth durability (case adoption, practice conversion, international penetration),
  • Gross margin trajectory driven by scale, yield, and product mix, and
  • Operating leverage as the installed base and workflow ecosystem mature.

Market participants often anchor to revenue-based multiples (e.g., EV/Sales) given the category’s growth-orientation, but the most material swing factors generally relate to sustainable case volume, mix improvement, and evidence of high-quality cash generation once scale effects mature.

🔍 Investment Takeaway

ALIGN TECHNOLOGY INC offers an ecosystem-based competitive position in clear aligners and digital orthodontics. The principal investment thesis rests on workflow-driven switching costs, cumulative clinical-software know-how, and digitized scale economics that together support durable practitioner adoption. While competitive dynamics and clinical/regulatory oversight remain meaningful risks, ALIGN’s integrated platform model is structurally harder to displace than a standalone aligner product supplier.


⚠ AI-generated — informational only. Validate using filings before investing.

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-06-30

"ALGN reported Q2 2026 revenue of $1.06B (+1.3% YoY; +1.6% QoQ) and net income of $108.3M (+13.1% YoY; -4.0% QoQ). EPS was $1.51 (vs. $1.72 in Q2’25; +? QoQ check: $1.51 vs $1.58 in Q1’26, -4.4% QoQ). Profitability improved on a gross basis (gross margin 71.7% in Q2’26 vs 70.8% in Q1’26 and 69.9% in Q2’25), but operating/net margins softened sequentially: operating margin declined to 11.7% from 16.6% in Q1’26, and net margin fell to 10.3% from 10.8% QoQ. Over the last four quarters, margins were volatile—net margin was far higher in Q4’25 (13.0%) and weakest in Q3’25 (5.7%). Cash flow remained positive: operating cash flow was $192.8M and free cash flow $223.5M (both QoQ and YoY improving vs Q2’25 OCF/$128.7M and FCF/$153.9M). The company continued shareholder-friendly capital allocation via buybacks (repurchased $31.2M of stock in Q2’26; dividends paid were $0). Balance sheet resilience is strong with $1.10B cash and equivalents and net cash position (net debt -$1.02B). Total shareholder returns appear solid but not explosive: price is up ~13.7% over 1Y (below the 20% momentum threshold), while valuation remains high (price/EPS ~27.9)."

Revenue Growth

Positive

Q2’26 revenue grew +1.3% YoY ($1.056B vs $1.012B) and +1.6% QoQ ($1.056B vs $1.040B), indicating steady but modest top-line momentum.

Profitability

Neutral

Gross margin expanded to 71.7% (from 70.8% QoQ; 69.9% YoY), but operating and net margins contracted QoQ (operating margin 11.7% vs 16.6% in Q1’26; net margin 10.3% vs 10.8%). EPS eased QoQ.

Cash Flow Quality

Good

Strong profitability-to-cash conversion: operating cash flow $192.8M and free cash flow $223.5M in Q2’26. Positive OCF/FCF supports ongoing buybacks; dividends are $0.

Leverage & Balance Sheet

Strong

Net cash position improved further (net debt -$1.02B in Q2’26 vs -$0.94B in Q1’26 and -$0.78B in Q2’25). Equity remains robust ($4.23B) and leverage is low.

Shareholder Returns

Neutral

Capital return supported by buybacks ($31.2M in Q2’26). Price performance is positive but not high-momentum: 1Y change +13.7% (below >20% threshold). No dividend yield.

Analyst Sentiment & Valuation

Neutral

Consensus target ~$204.9 vs price ~$190.1 implies upside of ~7.8%. Valuation is still elevated (price/EPS ~27.9), which caps the score absent re-acceleration in earnings quality.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

So What? ALGN’s Q2 showed clear aligner strength (+8.2% revenue; +7.4% volume) with non-GAAP operating margin expansion to 22.9% (+1.6 pts YoY), indicating the core Invisalign engine is executing despite volatile macro. The offsetting drag was Systems & Services (-10.8% revenue) as the company intentionally shifts iTero’s commercial model toward lower upfront-cost configurations and leasing/rental, which depress reported scanner revenue and ASPs while building an installed base and recurring platform economics. A major near-term swing factor is the U.K. VAT reversal: a ~$37.5M liability and 20% VAT effective Sept 7, 2026, with appeal uncertainty. Guidance reflects this trade-off: Q3 revenue down sequentially, GAAP gross margin down ~3–4 pts from one-time charges, while FY2026 assumes iTero shipments up double-digits and Clear Aligner volume up ~6% with ASP flat-to-slightly down. Overall, momentum is intact, but reported growth is constrained by deliberate scanner mix and regulatory/tax noise.

AI IconGrowth Catalysts

  • Record Clear Aligner shipments of 692,000 cases (+7.4% YoY) driven by increased doctor adoption and higher utilization across APAC, EMEA, Latin America, partially offset by North America retail softness
  • Record 89,200 doctors submitting Invisalign cases (+3.4% YoY) and doctor utilization +3.8% YoY
  • Teen/growing patient momentum: Invisalign treatment starts +7.2% YoY to 240,000 cases supported by China, Japan, Turkey, India, Brazil; continued adoption of Invisalign First, Invisalign Palatal Expander, and Invisalign MOAB
  • iTero Lumina adoption driving iTero scanner placements to new doctors at record levels (double-digit YoY) with active scanner units growing double-digits YoY; 12.4M+ scans performed (+16% YoY) supporting downstream Align Digital Platform utilization

Business Development

  • exocad: hosted Insights 2026 with 850+ dental professionals from 44+ countries and launched exocad ART (Advanced Restorative Treatment) combining tooth alignment and restorative treatments within exocad software

AI IconFinancial Highlights

  • Revenue: $1.0562B (+4.3% YoY), in line with outlook; constant currency benefit +$12.5M (+1.2%) YoY
  • Clear Aligner: revenue $870.9M (+8.2% YoY) supported by higher volume, price increases, lower net deferrals, and favorable FX; Clear Aligner ASP $1,260 (+0.8% YoY, +$10/case) offset by mix shift to lower-priced countries/products and higher discounts
  • Systems & Services: revenue $185.3M (-10.8% YoY) driven by lower scanner ASPs and shift to lower-priced scanners and flexible acquisition models (leasing/rental) vs upfront purchases
  • Gross margin: total 71.7% (+1.8 pts YoY) benefiting from operational efficiencies, tariff refund, and higher Clear Aligner ASPs; FX unfavorable -0.8 pts YoY
  • Non-GAAP operating margin: 22.9% (+1.6 pts YoY; +3.1 pts at constant currency); GAAP operating margin 14.6% (-~1.5 pts YoY) with FX unfavorable ~-1.4 pts YoY
  • Tax: GAAP effective tax rate 27.2% vs 28.2% prior year; non-GAAP tax rate 20% (long-term projected rate); EPS impacted by FX -$0.23 YoY
  • U.K. VAT: Upper Tribunal overturned VAT-exempt qualification; effective Sept 7, 2026 invoices include 20% U.K. VAT; recorded estimated liability ~$37.5M (incl. interest); impact tied to prior period stopping VAT charge effective Aug 1, 2025

AI IconCapital Funding

  • Share repurchases: Q2 2026 repurchased ~393,400 shares at average $169.45; total ~$67M under $200M open market repurchase plan expected to complete in Oct 2026
  • Updated full-year 2026 buyback intent: repurchase aggregate ~$400M to $500M during 2026 (inclusive of ~$133M expected through Oct 2026)
  • Remaining capacity under prior $1B program: $733.3M available as of June 30, 2026
  • Liquidity: cash & cash equivalents $1,102.6M as of June 30, 2026 (+$201.4M YoY)

AI IconStrategy & Ops

  • Scanner business model evolution: increasing adoption of lower-cost iTero Lumina configurations (e.g., PC, certified preowned) and leasing/rental programs that reduce upfront revenue but expand access and grow recurring platform revenue; management explicitly frames as intentional near-term revenue/profit trade-off
  • Margin drivers: lower refinement rates, improved treatment predictability, higher manufacturing throughput; product/configuration strategy (e.g., Comp 3-in-3, DSP Touch-Up) supports gross margin and cash conversion despite lower upfront pricing
  • Digital workflow enablement: launched integrated digital capabilities (integrated buttons, custom trim lines, specific 3D-printed attachments) with Invisalign Palatal Expander platform to strengthen imaging-to-planning-to-delivery connectivity
  • Doctor/channel productivity programs: patient financing, clinical support programs, doctor subscription offerings (DSP), and practice productivity solutions to support adoption, utilization, and conversion

AI IconMarket Outlook

  • Q3 2026 revenue: $1.00B to $1.020B (down sequentially from Q2)
  • Q3 2026 Clear Aligner volume: up mid-single digits YoY; Q3 Clear Aligner ASPs down sequentially due to geographic mix and FX
  • Q3 2026 Systems & Services revenue: down sequentially and YoY due to seasonality and continued mix shift to lower-priced scanners and flexible acquisition models (leasing/rental, certified preowned)
  • Q3 2026 GAAP gross margin: 67.5% to 68.5% (down ~3–4 pts sequentially) driven by onetime charges ~$20M–$30M mainly accelerated depreciation and restructuring/other charges
  • Q3 2026 non-GAAP gross margin: ~71% (down sequentially due to lower ASPs)
  • Q3 2026 GAAP operating margin: 13.5% to 15% (onetime charges ~$35M–$50M mainly restructuring/other charges and accelerated depreciation); Q3 2026 non-GAAP operating margin: ~24%
  • FY 2026: revenue growth up ~3% to 4% YoY; FX benefit assumption consistent with initial outlook; FX effect moderating to ~100 bps in remaining quarters
  • FY 2026: Clear Aligner volume growth ~6% YoY; Clear Aligner ASP flat to slightly down vs 2025; Systems & Services revenue down ~6% to 8% YoY
  • FY 2026: iTero shipments up double digits YoY; GAAP gross margin ~70.2% to 70.5%; GAAP operating margin ~15.1% to 15.6%; non-GAAP gross margin up ~100 bps; non-GAAP operating margin ~23% (~100 bps improvement YoY)

AI IconRisks & Headwinds

  • U.K. VAT adverse ruling: estimated ~$37.5M liability (incl. interest) and 20% VAT applied on applicable Invisalign aligners and Vivera retainers effective Sept 7, 2026; appeal subject to uncertainty
  • Systems & Services reported revenue pressure from lower scanner ASPs and mix shift toward leasing/rental and certified preowned options that lower upfront revenue
  • Macro/interest rate sensitivity impacting capital equipment demand (iTero scanner placements and capital equipment market described as pressured by higher interest rates and macro uncertainty)
  • FX and mix: margins and revenue impacted by unfavorable foreign exchange in multiple line items (e.g., total gross margin -0.8 pts YoY; operating margin FX -1.4 pts YoY)

Q&A: Analyst Interest

  • Case starts confidence vs macro risk: Management emphasized global mix durability—APAC double-digit growth, Europe strength, and North American DSO strength—stating confidence comes from regional offsetting rather than expecting macro to help. They cited quarterly results as proof of marketplace “dexterity” across segments.
  • North America independent “green shoots” (excluding DSOs): Management pointed to orthodontic conference enthusiasm and said it’s driven by innovation fit (e.g., Mandibular Advancement with Occlusal Blocks, IPE) plus DSP momentum. For “no-AA,” they described it as matching consumer affordability needs without relying on improved macro conditions.
  • Systems & Services guidance bridge (midpoint) and ASP assumption: The analyst asked how a ~$55M revenue delta vs prior expectation could be explained between higher volume and slightly higher ASP assumptions, and questioned why ASP was higher than expected in Q2. The transcript cuts off before management’s detailed reconciliation.

Sentiment: MIXED

Note: This summary was synthesized by AI from the ALGN Q2 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
© 2026 Stock Market Info — Align Technology, Inc. (ALGN) Financial Profile